Arcellx (Arcellx) Debt-to-Equity : 0.20 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Arcellx Debt-to-Equity?

Arcellx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $46.8 Mil. Arcellx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $50.8 Mil. Arcellx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $485.4 Mil. Arcellx's debt to equity for the quarter that ended in Dec. 2023 was 0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Arcellx's Debt-to-Equity or its related term are showing as below:

ACLX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2 Med: 0.32 Max: 0.43
Current: 0.2

During the past 5 years, the highest Debt-to-Equity Ratio of Arcellx was 0.43. The lowest was 0.20. And the median was 0.32.

ACLX's Debt-to-Equity is ranked worse than
56.22% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs ACLX: 0.20

Arcellx Debt-to-Equity Historical Data

The historical data trend for Arcellx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcellx Debt-to-Equity Chart

Arcellx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.43

0.20

Arcellx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										0.43	0.29	0.32	0.41	0.20

Competitive Comparison of Arcellx's Debt-to-Equity

For the Biotechnology subindustry, Arcellx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcellx's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcellx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Arcellx's Debt-to-Equity falls into.

Arcellx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Arcellx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(46.784	+	50.841)	/	485.38
	=	0.20

Arcellx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(46.784	+	50.841)	/	485.38
	=	0.20

Arcellx (NAS:ACLX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Arcellx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Arcellx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcellx (Arcellx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878

Website

https://www.arcellx.com

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Executives

Michelle Gilson	officer: Chief Financial Officer	25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG MD 20878
Christopher Heery	officer: Chief Medical Officer	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Rami Elghandour	director, officer: See Remarks	15 BARCELONA CIR, REDWOOD CITY CA 94065
Jill Carroll	director	C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Olivia C Ware	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Sr One Capital Management, Llc	10 percent owner	985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Sr One Co-invest Ii Manager, Llc	10 percent owner	985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093